Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00622336 · OUTCOME

Time to Progression

A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma · Source last updated 2019-11-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 70 months

What was measured

Time to progression based on the myeloma response determination criteria developed by Bladé et al 1998 and is defined as the time from registration to the first documented progression. The progressive disease criteria included increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

Analysis population: Time to progression not analyzed per the sponsors decision.

Groups in this outcome

Lenalidomide 25mg

Lenalidomide 25mg by mouth (PO) daily on Days 1 to 21 in each 28 day cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Lenalidomide 25mg0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Time to progression based on the myeloma response determination criteria developed by Bladé et al 1998 and is defined as the time from registration to the first documented progression. The progressive disease criteria included increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.
groups
  1. description
    Lenalidomide 25mg by mouth (PO) daily on Days 1 to 21 in each 28 day cycle
    id
    OG000
    title
    Lenalidomide 25mg
population Description
Time to progression not analyzed per the sponsors decision.
reporting Status
POSTED
time Frame
Up to 70 months
title
Time to Progression
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice